Autoimmune Pulmonary Alveolar Proteinosis clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for

  • Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    Sorry, in progress, not accepting new patients

    160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

    Los Angeles 5368361, California 5332921 and other locations

Last updated: